SAN FRANCISCO – February 12, 2013 – New findings from a landmark clinical trial show that although certain gene variants may predict whether a person is likely to develop age-related macular degeneration (AMD), a potentially blinding eye disease that afflicts more than nine million Americans, these genes do not predict how patients will respond to Lucentis™ and Avastin™, the two medications most widely used to treat the "wet" form of AMD. This new data from the Comparison of AMD Treatment Trials (CATT), published online in Ophthalmology, the journal of the American Academy of Ophthalmology, found no significant association between four gene variants and outcomes that measured the patients' responses to treatment.
The CATT genetics research team wanted to learn whether the major AMD risk genes could be useful in tailoring treatment with Avastin and Lucentis to individual patients' needs to boost treatment effectiveness and safety for patients. The main CATT study had confirmed that both medications significantly reduce or even reverse vision loss in many patients with wet AMD, but that study also found that treatment effectiveness varied among patients. The CATT genetics study, led by Stephanie Hagstrom, Ph.D., at the Cole Eye Institute at the Cleveland Clinic, clearly showed that the major AMD risk alleles do not predict patients' response to treatment.
This genetics study cohort comprised 73 percent of the 1,149 CATT participants. Cohort patients were evaluated for four gene variants linked to AMD risk: CFH, ARMS2, HTRA1, and C3. The patients' genotypes were then compared to their responses to treatment with Lucentis or Avastin. Both medications are anti-vascular epithelial growth factor (anti-VEGF) therapies that work in similar ways to reduce or prevent abnormal blood vessel growth and leakage. The researchers found no significant associations among the four gene variants and the outcomes that measured the patients' responses to treatment, which were improvement or loss of visual acuity, the status of the retinal anatomy, and the number of medication injections given.
"Our genetic research team remains hopeful that gene variants that predict patient response to AMD treatments will be identified soon," said Dr. Hagstrom. "This would enable a significant leap forward in ophthalmologists' ability to individualize treatment and care plans for their patients."
The main CATT study was a multi-center clinical trial that was funded by the National Institutes of Health and led by Daniel F. Martin, M.D., Chairman of the Cole Eye Institute at the Cleveland Clinic. The study compared Lucentis and Avastin for effectiveness and safety in treating the wet form of AMD.
The findings of the CATT genetic study lend further weight to the American Academy of Ophthalmology's 2012 recommendation on the use of genetic testing . This study assessed the same four major gene variants that are most widely used in current AMD genetic tests and found that the treatment response in patients who carried the gene variants was no better or worse than in patients who did not. The Academy advises against routine genetic testing for AMD and other complex eye disorders until specific treatment or monitoring strategies have been shown in clinical trials to be of benefit to people with specific, risk-linked genotypes.
Wet AMD, also called neovascular AMD, can severely damage vision if not treated in time. About 10 percent of patients suffer from the wet form, in which abnormal blood vessels grow underneath the retina, the tissue at the back of the eye that is crucial to good vision. These vessels leak fluid or blood, which blurs or distorts the central vision that enables people to read, recognize faces, drive, and perform other daily activities. Scientists now think that about half of all cases of AMD are related to specific genes.
The American Academy of Ophthalmology recommends that everyone learn their risks for AMD and other common age-related eye diseases. People who are Caucasian, have a family history of AMD, are smokers, or have cardiovascular problems are more susceptible to AMD and may need to be followed closely by their ophthalmologist, a medical doctor who specializes in the diagnosis, medical and surgical treatment of eye diseases and conditions. To learn more about AMD, its risk factors and treatment options, visit geteyesmart.org.
Note to media: Contact Media Relations to request full text of the study and arrange interviews with experts
About the American Academy of Ophthalmology
The American Academy of Ophthalmology is the world's largest association of eye physicians and surgeons — Eye M.D.s— with more than 32,000 members worldwide. Eye health care is provided by the three "O's" – ophthalmologists, optometrists, and opticians. It is the ophthalmologist, or Eye M.D., who can treat it all: eye diseases, infections and injuries, and perform eye surgery. For more information, visit www.aao.org The Academy's EyeSmart® program educates the public about the importance of eye health and empowers them to preserve healthy vision. EyeSmart provides the most trusted and medically accurate information about eye diseases, conditions and injuries. OjosSanos™ is the Spanish-language version of the program. Visit www.geteyesmart.org or www.ojossanos.org to learn more.
About Ophthalmology
Ophthalmology, the official journal of the American Academy of Ophthalmology, publishes original, peer-reviewed reports of research in ophthalmology, including basic science investigations and clinical studies. Topics include new diagnostic and surgical techniques, treatment methods, instrument updates, the latest drug findings, results of clinical trials, and research findings. Ophthalmology also publishes major reviews of specific topics by acknowledged authorities.
Journal
Ophthalmology